Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1
Name
s41467-017-01052-y.pdf
Size
1.3 MB
Format
Adobe PDF
Checksum (MD5)
fe266dfa110f4bd03e0a794212e38dd2
Author(s)
Feng, Yu-Xiong
Reinhardt, Ferenc
Jin, Dexter X.
Sokol, Ethan Samuel
Miller, Daniel Handel
Gupta, Piyush
Date Issued
October 2017
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Feng, Yu-Xiong et al. “Cancer-Specific PERK Signaling Drives Invasion and Metastasis through CREB3L1.” Nature Communications 8, 1 (October 2017): 1079 © 2017 The Authors
Version
Final published version
Abstract
PERK signaling is required for cancer invasion and there is interest in targeting this pathway for therapy. Unfortunately, chemical inhibitors of PERK's kinase activity cause on-target side effects that have precluded their further development. One strategy for resolving this difficulty would be to target downstream components of the pathway that specifically mediate PERK's pro-invasive and metastatic functions. Here we identify the transcription factor CREB3L1 as an essential mediator of PERK's pro-metastatic functions in breast cancer. CREB3L1 acts downstream of PERK, specifically in the mesenchymal subtype of triple-negative tumors, and its inhibition by genetic or pharmacological methods suppresses cancer cell invasion and metastasis. In patients with this tumor subtype, CREB3L1 expression is predictive of distant metastasis. These findings establish CREB3L1 as a key downstream mediator of PERK-driven metastasis and a druggable target for breast cancer therapy.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/S41467-017-01052-Y
